GLP-1 and GLP-2 as intestinal reparative therapies in inflammatory bowel disease: mechanisms, translation, and clinical opportunity - Takeaways - MDSpire

GLP-1 and GLP-2 as intestinal reparative therapies in inflammatory bowel disease: mechanisms, translation, and clinical opportunity

  • By

  • Joseph J. Lee

  • Pratikiran Bajgain

  • Amy L. Lightner

  • May 18, 2026

  • 0 min

Share

  • 1

    Inflammatory bowel disease (IBD) is a chronic condition characterized by relapsing inflammation in the gastrointestinal tract.

  • 2

    Current IBD management emphasizes intestinal reparative therapy to achieve objective healing endpoints rather than just symptom control.

  • 3

    Glucagon-like peptides (GLP-1 and GLP-2) are emerging therapeutic agents that promote epithelial integrity and modulate inflammation in IBD.

  • 4

    GLP-1 enhances mucosal healing and downregulates proinflammatory cytokines, indicating its potential role in IBD treatment.

  • 5

    Research is focusing on GLPs as actionable targets for restoring gut barrier integrity and improving long-term outcomes in IBD.

Original Source(s)

GLP-1 and GLP-2 as intestinal reparative therapies in inflammatory bowel disease: mechanisms, translation, and clinical opportunity

  • by Joseph J. Lee, Pratikiran Bajgain, Amy L. Lightner

  • May 18, 2026

Related Content

Progression of Coronary Calcium Detected on Routine Chest CT Enhances Cardiovascular Risk Assessment in Individuals with Inflammatory Bowel Disease: Findings from a Multicenter Study

Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease

Melatonin-induced restoration of the intestinal mucosal barrier in inflammatory bowel disease via activation of the SIRT1-LKB1-pAMPK axis